Cortometrajes de vídeo

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Dr. Joseph Mikhael explains the triad of maintaining the patients on term Lenalidomide maintenance.

Learn about successful treatment of 72 year old Renal Cell Carcinoma Patient also suffering from Rheumatoid Arthritis treated with single agent TKI

Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.

Newer treatments like immunotherapy are associated with myocarditis which has high fatality rates & cardiovascular issues arising of CART cell therapy are often attributed to Cytokine Release Syndrome (CRS).

Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.

High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

Brain metastases are commonly observed in patients with Lung cancer, Breast Cancer & Melanoma. Breast Cancer patients are living longer & eventually develop Brain Metastases.